CAVAX
Price
$18.62
Change
+$0.09 (+0.49%)
Updated
Jun 2 closing price
Net Assets
451.11M
RWMEX
Price
$68.20
Change
+$0.27 (+0.40%)
Updated
Jun 2 closing price
Net Assets
214.46B
Interact to see
Advertisement

CAVAX vs RWMEX

Header iconCAVAX vs RWMEX Comparison
Open Charts CAVAX vs RWMEXBanner chart's image
CAVAX vs RWMEX Comparison Chart in %
View a ticker or compare two or three
VS
CAVAX vs. RWMEX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAVAX is a Buy and RWMEX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RWMEX has more cash in the bank: 214B vs. CAVAX (451M). RWMEX pays higher dividends than CAVAX: RWMEX (1.15) vs CAVAX (0.76). CAVAX was incepted earlier than RWMEX: CAVAX (11 years) vs RWMEX (24 years). CAVAX (1.31) is less costly to investors than RWMEX (0.60). RWMEX is a more actively managed with annual turnover of: 29.00 vs. CAVAX (21.00). RWMEX has a lower initial minimum investment than CAVAX: RWMEX (250) vs CAVAX (500). CAVAX annual gain was more profitable for investors over the last year : 15.73 vs. RWMEX (7.71). RWMEX return over 5 years is better than : 24.95 vs. CAVAX (15.29).
CAVAXRWMEXCAVAX / RWMEX
Total Expense Ratio0.780.60130%
Annual Report Gross Expense Ratio1.310.60218%
Fund Existence11 years24 years-
Gain YTD9.3225.446171%
Front LoadN/AN/A-
Min. Initial Investment500250200%
Min. Initial Investment IRAN/AN/A-
Net Assets451M214B0%
Annual Yield % from dividends0.761.1566%
Returns for 1 year15.737.71204%
Returns for 3 years45.8431.72144%
Returns for 5 years15.2924.9561%
Returns for 10 years115.0982.28140%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMBA78.382.71
+3.57%
Ambarella
ORRF37.580.87
+2.37%
Orrstown Financial Services
IREN66.611.28
+1.95%
IREN Limited
SCKT0.90-0.04
-4.26%
Socket Mobile
KZIA11.79-0.77
-6.13%
Kazia Therapeutics Limited